Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ:NAUT) will release its second quarter 2026 financial results before market open on Tuesday, July 28, 2026.
Management will host a webcast conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook, accessible via the company’s investor website.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings date: NAUT +5.33% in the Jul 8 session
In the Jul 8 session, NAUT gained 5.33%, reflecting a notable positive market reaction. Argus tracked a peak move of +13.6% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Earnings date notice | Neutral | -2.9% | Announced Q1 2026 earnings release timing and related webcast details. |
| Feb 05 | Earnings date notice | Neutral | -2.9% | Set date for Q4 and full-year 2025 financial results and conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings date announcements have previously coincided with modestly negative next-day price reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio